Home › Myelodysplastic Syndromes › North Carolina › Durham
Myelodysplastic Syndromes clinical trials in Durham, NC
14 studies for Myelodysplastic Syndromes are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
RecruitingPhase 1/2
- Duke Cancer Institute, Durham
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Duke University Medical Center, Durham
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
RecruitingPhase 1/2
- Duke Cancer Center, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
RecruitingPhase 1/2
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi away
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
RecruitingPhase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- Duke University, Durham
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RecruitingPhase 3
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RecruitingPhase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
Registry of Older Patients With Cancer
RecruitingObservational study
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecruitingPhase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi away
About Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.
More about Myelodysplastic Syndromes on MedlinePlus
Myelodysplastic Syndromes trials in other cities
- Houston, TX43 studies
- Baldwin Park, CA27 studies
- New York City, NY22 studies
- Seattle, WA21 studies
- Boston, MA20 studies
- Tampa, FL20 studies
- Washington, DC19 studies
- Miami, FL17 studies
- Columbus, OH14 studies
- Atlanta, GA13 studies
- Chicago, IL13 studies
- St. Louis, MO13 studies
Other studies in Durham
- Breast Cancer63 studies
- Cancer (all types)61 studies
- Non-Small Cell Lung Cancer42 studies
- Multiple Myeloma36 studies
- Acute Myeloid Leukemia34 studies
- Lung Cancer33 studies
- Metastatic Cancer33 studies
- Prostate Cancer32 studies
- Colorectal Cancer30 studies
- Ovarian Cancer28 studies
- Chronic Lymphocytic Leukemia28 studies
- Heart Failure25 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.